Status: Planned First registered on: 03/01/2020
Last updated on: 03/01/2020
1. Study identification
EU PAS Register NumberEUPAS32724
Official titleBiologics in severe asthma: utilization patterns, causes for discontinuation and switches
Study title acronymBiologics in severe asthma
Study typeObservational study
Brief description of the studyTo describe the use of biologics in patients with severe asthma, with respect to persistence and switch to another biologic, and how this relates to asthma outcomes. To describe the frequency, patterns, reasons and clinical outcomes for biologic treatment discontinuation and switching in a severe asthma cohort. To describe the demographical and clinical characteristics of severe asthma patients that discontinue or switch their biologic therapy, stratified by country.
Was this study requested by a regulator?No
Is the study required by a Risk Management Plan (RMP)? Not applicable
Regulatory procedure number (RMP Category 1 and 2 studies only)
Other study registration identification numbers and URLs as applicable
2. Research centres and Investigator details
Coordinating study entity
Centre nameOptimum Patient Care Global Limited (OPCG)
Centre locationUK
Details of (Primary) lead investigator
Title Professor
Last name Price
First name David
Is this study being carried out with the collaboration of a research network?
Yes

Optimum Patient Care (OPC)
Respiratory Effectiveness Group (REG)
Other centres where this study is being conducted
Not applicable (single centre)

Countries in which this study is being conducted
International study

Singapore
United Kingdom
3. Study timelines: initial administrative steps, progress reports and final report
PlannedActual
Date when funding contract was signed20/12/2018
Start date of data collection31/10/2019
Start date of data analysis01/06/2019
Date of interim report, if expected
Date of final study report01/10/2019
4. Sources of funding
Please provide estimates of the percentage of funding by source for this study
Names(s)Approximate % funding
Pharmaceutical companiesAstraZeneca50
CharitiesOPCG50
Government body
Research councils
EU funding scheme
5. Contact details for enquiries
Scientific Enquiries
Title Professor
Last name Price
First name David
Address line 15 Coles Lane
Address line 2 
Address line 3 
CityOakington, Cambridge 
PostcodeCB24 3BA 
CountryUnited Kingdom
Phone number (incl. country code)44-7787-905057 
Alternative phone number 
Fax number (incl. country code) 
Email address dprice@opri.sg
Public Enquiries
Title Professor 
Last name Price 
First name David 
Address line 15 Coles Lane 
Address line 2 
Address line 3 
CityOakington, Cambridge 
PostcodeCB24 3BA 
CountryUnited Kingdom 
Phone number (incl. country code)44-7787-905057 
Alternative phone number 
Fax number (incl. country code) 
Email address dprice@opri.sg 
Top